PMID- 35314257
OWN - NLM
STAT- MEDLINE
DCOM- 20220504
LR  - 20220504
IS  - 1872-8227 (Electronic)
IS  - 0168-8227 (Linking)
VI  - 186
DP  - 2022 Apr
TI  - Empagliflozin in patients with type 2 diabetes mellitus and chronic obstructive 
      pulmonary disease.
PG  - 109837
LID - S0168-8227(22)00649-0 [pii]
LID - 10.1016/j.diabres.2022.109837 [doi]
AB  - AIMS: Type 2 diabetes mellitus (T2DM) and chronic obstructive pulmonary disease 
      (COPD) often co-exist, yielding increased risk of cardiovascular (CV) 
      complications including heart failure (HF). We assessed risk of cardiorenal 
      outcomes, mortality and safety in patients with versus without COPD in the 
      EMPA-REG OUTCOME trial. METHODS: Patients (n = 7,020) with T2DM and CV disease 
      (CVD) were treated with empagliflozin (10 mg or 25 mg) or placebo. Cox regression 
      was used to assess COPD subgroup (placebo only) associations with, and treatment 
      effects of empagliflozin versus placebo on first hospitalization for HF (HHF), CV 
      death, all-cause mortality, incident/worsening nephropathy, and all-cause 
      hospitalization. RESULTS: At baseline, patients with COPD (n = 707) had more HF 
      and used insulin more frequently than those without COPD. During follow-up in the 
      placebo group, those with baseline COPD had increased risk of HHF (HR 2.15 [95% 
      CI 1.32, 3.49]), HHF/CV death (1.60 [1.10, 2.33]), incident/worsening nephropathy 
      (1.68 [1.26, 2.24]), all-cause hospitalization (1.44 [1.19, 1.74]) and all-cause 
      death (1.60 [1.09, 2.35]) compared to those without COPD. Empagliflozin 
      consistently reduced all clinical outcomes, irrespective of COPD status 
      (interaction p-values 0.14 to 0.96), with a confirmed safety profile. 
      CONCLUSIONS: In patients with T2DM and CVD, COPD increased the risk of mortality 
      and cardiorenal outcomes, including HF. Empagliflozin consistently reduced these 
      outcomes versus placebo regardless of COPD, suggesting that empagliflozin's 
      benefits in patients with T2DM and CVD are not mitigated by the presence of COPD.
CI  - Copyright (c) 2022 The Author(s). Published by Elsevier B.V. All rights reserved.
FAU - Anker, Stefan D
AU  - Anker SD
AD  - Department of Cardiology (CVK); and Berlin Institute of Health Center for 
      Regenerative Therapies (BCRT); German Centre for Cardiovascular Research (DZHK) 
      partner site, Berlin, Germany, Charite Universitatsmedizin Berlin, Berlin, 
      Germany; Institute of Heart Diseases, Wroclaw Medical University, Wroclaw, 
      Poland. Electronic address: s.anker@cachexia.de.
FAU - Sander, Leif-Erik
AU  - Sander LE
AD  - Department of Infectious Diseases and Respiratory Medicine, Charite 
      Universitatsmedizin Berlin, Berlin, Germany.
FAU - Fitchett, David H
AU  - Fitchett DH
AD  - St Michael's Hospital, Division of Cardiology, University of Toronto, Toronto, 
      ON, Canada.
FAU - Zinman, Bernard
AU  - Zinman B
AD  - Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, University of 
      Toronto, Toronto, ON, Canada.
FAU - Pernille Ofstad, Anne
AU  - Pernille Ofstad A
AD  - Boehringer Ingelheim Norway KS, Asker, Norway.
FAU - Wanner, Christoph
AU  - Wanner C
AD  - Wurzburg University Clinic, Wurzburg, Germany.
FAU - Vedin, Ola
AU  - Vedin O
AD  - Boehringer Ingelheim AB, Stockholm, Sweden.
FAU - Lauer, Sabine
AU  - Lauer S
AD  - Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany.
FAU - Verma, Subodh
AU  - Verma S
AD  - St Michael's Hospital, Division of Cardiac Surgery, University of Toronto, 
      Toronto, ON, Canada.
FAU - Yaggi, Henry K
AU  - Yaggi HK
AD  - Section of Pulmonary, Critical Care & Sleep Medicine, Yale University School of 
      Medicine, New Haven, CT, USA.
FAU - Inzucchi, Silvio E
AU  - Inzucchi SE
AD  - Yale University School of Medicine, New Haven, CT, USA.
LA  - eng
PT  - Journal Article
DEP - 20220318
PL  - Ireland
TA  - Diabetes Res Clin Pract
JT  - Diabetes research and clinical practice
JID - 8508335
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Glucosides)
RN  - 0 (Hypoglycemic Agents)
RN  - HDC1R2M35U (empagliflozin)
SB  - IM
MH  - Benzhydryl Compounds/therapeutic use
MH  - *Cardiovascular Diseases/drug therapy
MH  - *Diabetes Mellitus, Type 2/complications/drug therapy
MH  - Female
MH  - Glucosides/adverse effects
MH  - *Heart Failure/drug therapy
MH  - Humans
MH  - Hypoglycemic Agents/therapeutic use
MH  - *Kidney Diseases/drug therapy
MH  - Male
MH  - *Pulmonary Disease, Chronic Obstructive/complications/drug therapy
MH  - Treatment Outcome
OTO - NOTNLM
OT  - (5/6)
OT  - COPD
OT  - Cardiovascular diseases
OT  - Emphysema
OT  - Heart failure
OT  - Type 2 diabetes mellitus
EDAT- 2022/03/23 06:00
MHDA- 2022/05/06 06:00
CRDT- 2022/03/22 05:34
PHST- 2021/12/14 00:00 [received]
PHST- 2022/02/16 00:00 [revised]
PHST- 2022/03/16 00:00 [accepted]
PHST- 2022/03/23 06:00 [pubmed]
PHST- 2022/05/06 06:00 [medline]
PHST- 2022/03/22 05:34 [entrez]
AID - S0168-8227(22)00649-0 [pii]
AID - 10.1016/j.diabres.2022.109837 [doi]
PST - ppublish
SO  - Diabetes Res Clin Pract. 2022 Apr;186:109837. doi: 10.1016/j.diabres.2022.109837. 
      Epub 2022 Mar 18.